EnEvolv leverages a proprietary genome engineering platform built on Multiplex Automated Genome Engineering (MAGE) technology to develop and license microorganisms for production of chemicals, enzymes and small molecules. Its target markets include pharmaceuticals, personal care, specialty chemicals, food, and energy industries. The company collaborates with major companies to engineer novel microorganisms and improve existing strains to increase production yield and product quality. EnEvolv completed a $1.7M Series A financing and will use the proceeds to expand research and development and business development activities. The company was co-founded by Marco Farsheed (Chief Executive Officer), George Church of Harvard Medical School and Farren Isaacs of Yale University. It also appointed Ron Meeusen and Charles L. Cooney to its board of directors.

Total raised

$2M

Funding rounds

1

Latest round

Series A

Latest activity

Mar 2014